Table 2.
Demographic and clinical characteristics of the two cohorts.
| Parameters | Cohort A (n = 131) | Cohort B (n = 120) | P value |
|---|---|---|---|
| Age (y, M ± SD) | 49.28 ± 11.96 | 51.33 ± 7.33 | 0.438 |
| Gender (M/F) | 56/75 | 57/63 | 0.450 |
| BMI (kg/m2, M ± SD) | 24.25 ± 3.40 | 22.34 ± 2.73 | <0.001 |
| HCV genotype (1b/2a/unknown) | 62/46/23 | 45/52/23 | 0.274 |
| HCV RNA (+/−) | 121/10 | 100/20 | 0.028 |
| TBIL (μmol/L) | 12.9 (9.5, 18.4) | 15.3 (11.2, 19.1) | 0.014 |
| ALT (U/L) | 43.0 (26.0, 81.0) | 37.6 (29.4, 65.9) | 0.684 |
| AST (U/L) | 48.0 (29.0, 69.0) | 35.4 (28.1, 47.7) | 0.024 |
| GGT (U/L) | 34.0 (18.0, 66.0) | 15.4 (12.3, 25.1) | <0.001 |
| ALB (g/L, M ± SD) | 39.30 ± 4.28 | 43.21 ± 2.36 | <0.001 |
| GLB (g/L) | 31.0 (27.0, 35.0) | 27.2 (25.0, 30.4) | <0.001 |
| PA (mg/L, M ± SD) | 166.63 ± 49.78 | 171.41 ± 36.96 | 0.392 |
| RBC (1012/L, M ± SD) | 4.41 ± 0.49 | 4.76 ± 0.67 | <0.001 |
| PLT (109/L, M ± SD) | 151.95 ± 66.69 | 171.36 ± 53.20 | 0.011 |
| PT (s) | 11.3 (10.6, 12.1) | 11.5 (11.0, 11.9) | 0.003 |
| GP73 (ng/mL, M ± SD) | 92.22 ± 57.26 | 85.80 ± 29.09 | 0.573 |
| Necroinflammation activity grade (G: 0-1/2/3/4) | 50/48/7/- | 17/67/34/2 | <0.001 |
| Fibrosis stage (F: 0-1/2/3/4) | 35/30/31/35 | 56/50/12/2 | <0.001 |
Continuous variables were expressed as mean ± standard deviation (SD) or median and interquartile range (IQR). BMI: body mass index; HCV: hepatitis C virus; TBIL: total bilirubin; ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT: gamma glutamyltransferase; ALB: albumin; GLB: globulin; PA: prealbumin; RBC: red blood cell; PLT: platelet; PT: prothrombin time; GP73: Golgi protein 73.